ArticleMolecular imaging and biology2014
GRP receptor imaging of prostate cancer using [(99m)Tc]Demobesin 4: a first-in-man study.
Article in Molecular imaging and biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 56 citations in OpenAlex.
- Synthesis and in vitro evaluation of pharmacokinetically optimizedEJNMMI radiopharmacy and chemistry · 2026Article
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Phase I Clinical Study with the GRPR-Antagonist [Pharmaceutics · 2025Article
- Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands.EJNMMI research · 2025Article
- Optimized Production ofNuclear medicine and molecular imaging · 2024Article
- Biodistribution and radiation dosimetry of [EJNMMI research · 2024Article
- Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Phase I Trial of [Cancers · 2023Article
- Imaging Properties and Tumor Targeting ofBiomedicines · 2022Article
- Optimization of the Pharmacokinetic Profile of [Pharmaceuticals (Basel, Switzerland) · 2022Article
- Radiolabeled Bombesin Analogs.Cancers · 2021Review
- Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review.Journal of clinical medicine · 2021Review
- [Cancers · 2021Article
- Preclinical Evaluation ofPharmaceutics · 2021Article
- One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [Pharmaceutics · 2020Article
- Localization ofPharmaceuticals (Basel, Switzerland) · 2019Article
- Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors.Molecular imaging and biology · 2018Review
- Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonistEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
Abstract
purposeWe explored the imaging of bombesin receptors and evaluated the clinical use of [(99m)Tc]Demobesin 4 ([(99m)Tc]DB4) in prostate cancer patients. PROCEDURES: [(99m)Tc]DB4 was prepared according to Good Manufacturing Practice. Patients with prostate cancer underwent serial planar and SPECT imaging up to 3 h after administration. Blood and urine samples were taken to assess pharmacokinetics.
results[(99m)Tc]DB4 is safe and clears rapidly from the bloodstream via the kidneys resulting in low background activity. The tracer binds strongly to the gastrin-releasing peptide receptor (GRPR) in vivo as indicated by the high uptake in the pancreas seen in all patients. In patients who had undergone hormone therapy, [(99m)Tc]DB4 did not efficiently image metastatic prostate cancer. In contrast, in newly diagnosed patients local disease was visualised.
conclusionsThe GRPR is an unsuitable target for imaging refractory prostate cancer but may be useful in untreated disease. [(99m)Tc]DB4 is a promising radiopharmaceutical which merits further exploration in this specific group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.